February 7, 2014
The landscape of hepatitis C (HCV) management has undergone a near-fundamental transformation over the past couple of years. As new treatment options puff up like popcorn kernels on a hot stove and our understanding of the virus deepens, it's important to revisit what's changed -- and what further changes 2014 may hold in store.
Late in 2013, Andrea Cox, M.D., Ph.D., an associate professor of medicine at Johns Hopkins University School of Medicine, presented an update on HCV coinfection for an audience of HIV care providers. Read on for a summary of key points from her talk, including selected slides (which have been reposted with her permission).
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|HIV-Positive Individuals on Treatment Lose More Years of Life to Smoking Than to HIV|
|More Age-Related Illnesses in Older People With HIV Than Comparable HIV-Negatives|
|This Week in HIV Research: HIV Reservoirs Remain Obstacles to Cure; "Redesigned" Antibodies Show Promise; and Is 85% Adherence Enough?|
|Advocates for Women Talk About CROI 2015|
|Novel, Broadly Active HIV Inhibitor Shows Potential for Vaccine|
|This Week in HIV Research: Another Route for Gene Therapy; Drugmaker and University Team Up for HIV Cure|